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Letters
HCV-RNA, is not yet routinely available and is limited by
false-positive or false-negative results.
Meanwhile, in order to reduce the incidence of HCV
infection, strict adherence to the universal precautions (CDC,
Atlanta) must be carried out. According to current knowledge
the application of these measures of hygiene is probably
sufficient to prevent HCV spread in the dialysis setting, and
the isolation of positive patients is not warranted.
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Sir,
I read Dr Beccari's contribution on the issue of nosocomial
spread of hepatitis C virus (HCV) infection among
haemodialysis patients with interest. He stresses another
controversial aspect of the problem; the isolation policy for
HCV-infected patients in dialysis units, and concludes that
if universal precautions are followed strictly, there is no need
for such an isolation policy.
I agree with Dr Beccari that adherence to universal precau-
tions is an essential measure in the prevention of nosocomial
blood-borne viral infections, but on the other hand I think
it is hard to draw a concrete conclusion about isolation
policies for the following reasons:
1. Molecular biological studies which show the presence
of viral genetic material in the haemodialysis ultrafiltrate
rather than the ones which fail to detect the viral RNA
should be regarded as important microbiological find-
ings. Apart from methodological differences and
errors, the degree of viraemia of a patient is probably
an important factor in the contamination of the
ultrafiltrate.
2. Haemodialysis treatment itself is a well-established risk
factor for acquiring HCV infection [1], especially if the
same machine is shared by more than four patients [2].
3. In the previous decade isolation policies for hepatitis B
virus (HBV) infection, which shares common routes of
transmission with HCV, has been successful in reducing
the nosocomial transmission of HBV infection in dialysis
units, and isolation policies for HBV-infected dialysis
patients are mandatory.
4. The risk of acquiring nosocomial HCV infection is
strikingly different in units with a low rate of infection
from those in which 50-70% of chronic dialysis patients
are infected.
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5. The issue becomes more complex when one remembers
the lack of protective effect of anti-HCV antibodies,
different infectivity and pathogenicity potentials of dis-
tinct HCV strains, and studies showing dialysis patients
infected with more than one strain of HCV [3,4].
The answer to this controversy probably resides in the
data which will be derived from the molecular epidemiolog-
ical studies. Demonstration of a particular strain of HCV in
infected patients sharing the same machine and/or dialysis
unit will be an invaluable additional finding in favour of
nosocomial transmission. Unfortunately, as Dr Beccari
points out most of these molecular diagnostic tools are
inaccessible to the majority of physicians taking care of
dialysis patients.
I believe that isolation policies for HCV-infected dialysis
patients should be developed according to the prevalence
and rate of infection in a particular unit, and every effort
should be undertaken to prevent spread of infection to newly
admitted cases.
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Complement activation by LDL-apheresis using
dextran sulphate
Sir,
LDL-apheresis (LDL-aph) using dextran sulphate (DS)
adsorption has been used successfully as a therapeutic tool
to reduce LDL-cholesterol in familial hypercholesterolaemia
[1]. Anaphylactoid reactions have been reported in patients
treated with LDL-aph using DS columns [2]. These reactions
have been attributed to the release of bradykinin, a potent
vasodilator. However, artificial biomaterials can also activate
the complement system, which may play a major role in such
anaphylactoid reactions. We studied the effects of LDL-aph
with DS (Kaneka LA 15 Liposorber) on the complement
system during three apheresis sessions, in a 25-year-old
patient with familial hypercholesterolaemia.
Plasma samples were collected in EDTA before, during,
and after each procedure. Complement activation products
C4d, Bb, and SC5b-9 were measured with commercial kits
(Quidel). The concentrations of several proteins, CH50 and
AP50 were reduced after LDL-aph (see Table 1). As shown
in Figure 1, complement activation products Bb and SC5b-9
significantly increased at the end of LDL-aph (Bb, in ug/ml,
from 0.95 + 0.05 to 34.4+1.1; SC5b-9, inng/ml, from
25.0 + 4.5 to 830 + 334); however, there was no significant
increase in C4d. Of note, plasma samples coming out of the
DS column were practically devoid of factor H, and had
increased concentrations of Bb and SC5b-9. There was also
1476 Letters
Table 1. Complement measurements after LDL-apheresis in a
patient with familial hypercholesterolaemia"
Protein
C3
Factor B
D
H
I
Clq
Clr
Cls
C l inhibitor
C4
C9
CH50<
AP5OC
Total protein
Albumin
After LDL-apheresisb (%)
69.3 + 1.7
65.3 + 9.3
45.6 + 2.3
29.0+1.5
83.1 ±7.3
24.0 + 4.9
24.8
47.7
70.3 + 7.7
78.6±3.3
61.0+12.1
45.0 + 2.5
41.5±0.5
85.2 + 1.2
87.0±2.3
"Antigenic concentrations, except for factor D, CH50, AP50
(haemolytic assays). All values were in the normal range before
apheresis. Total protein and albumin are used as controls.
b
 Values are expressed as the percentage of the pre-apheresis levels.
Each value represents the mean + SEM from three different apheresis
sessions, except for Clr and Cls (single values).
c
 Standard haemolytic assays assessing classical pathway (CH50) and
alternative pathway (AP50) of complement.
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Fig. 1. Changes in the concentration of complement activation prod-
ucts Bb and SC5b-9, and of complement inhibitory protein factor
H, during LDL-apheresis with DS. Each value represents the mean
from two different apheresis sessions. Plasma samples: 1. Before
starting LDL-aph. 2. After separation of plasma from whole blood
with filter made of polysulphone, before DS column. 3. Plasma
coming out of DS column. 4. At the end of LDL-aph. 5. Two hours
after the end of LDL-aph. 6. Twenty-four hours after the end of
LDL-aph.
a marked C3c formation (C3 conversion to C3c) as assessed
by double immunodiffusion (from <1% to 28.6 + 3.5%, at
the end of LDL-aph). Twenty-four hours after a normal
LDL-aph session, no C3c was detectable in plasma, and
CH50, AP50 had increased to 72 and 86%, respectively.
In two sessions of LDL-aph, the neutrophil count (per
microlitre) declined from 3875 + 31 to 1645±11 after 2 h of
LDL-aph.
The main finding of this study was the strong activation
of the alternative pathway (AP) of complement during LDL-
aph using DS, probably due to its deregulation in the fluid
phase because of the reduction of factor H. We could not
demonstrate activation of the classical pathway. The signi-
ficant reduction in factor H (and Clq) was due to adsorption,
since more than 90% of these proteins were recovered in the
eluates from the DS columns. In vitro, previous work has
shown that the interaction of human serum with negatively
charged polystyrene sulphonate results in massive comple-
ment activation by the AP due to an immediate adsorption
of factor H [3]. Factor H is an essential inhibitory protein
of the AP under normal conditions; thus its adsorption or
in-vivo blockade results in hypercatabolism of the AP [3,4].
The resulting strong complement activation by the AP may
cause anaphylactoid reactions. Nafamostat mesilate, which
inhibits both complement activation and the release of brady-
kinin, may be the anticoagulant of choice for LDL-aph using
DS, in order to avoid potential life-threatening reactions [5].
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ACE inhibitors do not decrease rHuEpo response in
patients with end-stage renal failure
Sir,
Angiotensin-converting enzyme (ACE) inhibitors have been
successfully utilized to reduce haemoglobin concentrations
in patients with post-transplant erythrocytosis [1,2]. Some
authors have suggested that ACE inhibitors could decrease
serum erythropoietin levels [3] and bone-marrow erythro-
poiesis in ESRD [4]. In this way Walter [5] has suggested
that ACE inhibitors could reduce the efficacy of rHuEpo in
ESRD patients. However, other studies were unable to find
any effect of ACE inhibitors on haematocrit or rHuEpo
dose [6].
We have studied 252 patients on haemodialysis from 17
units; 48 of them were treated with ACE inhibitors. All
patients had been treated with rHuEpo for at least 6 months,
and to be included in the study a patient's haemoglobin had
to be over 9 g/dl in the 3 previous months. Age, sex, months
on rHuEpo treatment, months on HD, haemoglobin, haem-
atocrit, iron metabolism, iPTH, aluminium, B2-microglobulin
and Ul/kg/week of rHuEpo were monitored. The group
treated with ACE inhibitors was younger (51 + 14 versus
57+16 years, /><0.05), but both groups were similar in
